BioXcel to seek label update for psych drug Igalmi after Phase 3 success

BioXcel is taking the next step in an effort to update the label of its psychiatric drug Igalmi. A Phase 3 trial studying Igalmi enrolled schizophrenia or bipolar disorder patients who suffer episodes of agitation ...